Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 288 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Finding Hope in the New Year During COVID-19 and Cancer January 6, 2021 FDA Approves Acalabrutinib with Venetoclax for CLL or SLL March 4, 2026 Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline August 28, 2025 Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian Cancers May 4, 2018 Load more HOT NEWS Quarantined Cruise Ship Passenger Concerned She Won’t Make It Home for... On World Cancer Day, ESMO Renews a Longstanding Commitment to Closing... Mom with Breast Cancer Who Had A Year to Live Goes... Joining the dots: How our new research data strategy will unlock...
